

Commercial Medicines Unit

NHS England

2nd Floor, Rutland House

Runcorn, Cheshire

WA7 2ES

**All messages regarding the Offer documentation**

**should be sent via the Atamis Website:**

health.atamis.co.uk

**26 October 2022**

**Invitation to offer for:**

**Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023**

**Offer reference number: CM/PHR/22/5660**

**CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

**CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

**CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

**CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

NHS England (‘Authority’) invites offers for the above-mentioned goods and/or services as defined in Document No.03 Framework Agreement and Terms and Conditions. Offers shall be made subject to the terms of:

Document No.01 This covering letter

Document No.02 Terms of offer

Document No.03 Framework Agreement and Terms and Conditions

Document No.04a Quality Assurance Process

Document No.04b Assessment Criteria, Stability Protocol and Additional Specification Requirements

Document No.05 Selectt offer schedule instructions

Document No.05a Selectt Offer schedule – CM\_PHR\_22\_5660 (01, 02, 03 & 04)

Document No.05b Tender Product listing and usage – CM\_PHR\_22\_5660 (01, 02, 03 & 04)

Document No.06 Form of offer

Document No.07a Quality control technical sheet

Document No.07b Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines control technical sheet

Document No. 08 Confidential information schedule

Document No. 09 Tender Design and Instructions on completing the offer schedule

Document No. 10 Participating Authorities

all of which constitute this Invitation to offer.

If any of the documents constituting the Invitation to offer is missing please contact the undersigned immediately via the Atamis messaging portal.

The Authority does not bind itself to accept the lowest offer or any offer at all and reserves the right to accept an offer either in whole or in part, each item being for this purpose treated as offered separately. The Authority reserves the right to conclude a framework agreement for the supply of the goods and/or services with more than one Offeror.

I would like to draw your attention to the following important points when completing and submitting your offer:

1. All offers must be written in English.

2. All offers must be submitted subject to and in accordance with the documentation comprising the Invitation to offer. Save where the Offerors are instructed to provide information, the documentation comprising the Invitation to offer must not be amended in any way.

3. All offers submitted must be the same price for each offered lot.

4. All offers must be loaded onto the Commercial Medicines Unit’s eTendering portal health.atamis.co.uk

5. Offers must be open for 90 days.

6. Offers must be fully completed and available on the designated website no later than **13:00** on **28 November 2022**.

I must also draw your attention to the enclosed Form of offer where all the requirements for completing and submitting an offer can be found. Failure to comply with these instructions may result in your offer being rejected.

I hope that the above instructions are clear but please contact the undersigned via the Atamis messaging portal if there is anything you wish to clarify.

Yours faithfully

Katie Noonan

Sourcing Specialist

Branded, Biosimilars and IV Fluids Procurement Support